BioLife Solutions, Inc. (FRA:BJX1)

Market Cap	895.60M +0.9%
Revenue (ttm)	81.95M +28.9%
Net Income	-3.91M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	133.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	0
Open	18.50
Previous Close	19.20
Day's Range	18.50 - 18.50
52-Week Range	15.40 - 24.80
Beta	n/a
RSI	67.20
Earnings Date	May 7, 2026

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 155
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BJX1

Financial Performance

In 2025, BioLife Solutions's revenue was $96.21 million, an increase of 28.89% compared to the previous year's $74.65 million. Losses were -$4.60 million, -77.23% less than in 2024.

Financial numbers in USD